Brenzavvy® Launched in Rwanda
On Friday, June 20th, a meaningful milestone was reached in Rwanda’s healthcare journey. BAMCO Africa officially launched Brenzavvy® (bexagliflozin) 20mg, an oral medication for adults with Type 2 Diabetes.
Shared Vision and Forward Momentum
Markus Gemuend, Co-founder and CEO of BAMCO Africa, stated: “This is a major milestone for patients with type2 diabetes in Rwanda. Only two years after approval by the US FDA, this innovative SGLT2 inhibitor developed by TheracosBio is being made available by BAMCO Africa to patients in Rwanda. This is what BAMCO Africa is all about, ensuring all patients in Sub Saharan African countries get timely access to innovative treatments available in other parts of the world”.
Markus Gemuend, Co-founder and CEO
The program featured insights from renowned experts , who provided a powerful lens on managing Type 2 Diabetes in LMICs
Brian Connelly, President and CEO of Theracos Bio
Brian Connelly, President and CEO of Theracos Bio, joined the event live online, staying with the audience throughout and answering every question with clarity and humility. Brian stated that “Our goal for Brenzavvy is to make it available to patients in need around the world and we are excited to partner with BAMCO to bring this safe and effective treatment to patients in Rwanda with Type 2 diabetes mellitus.”
Teta Christa - Business Development Lead
A beautiful product reveal was led by BAMCO’s Teta Christa, followed by closing remarks from Mabeh Fang (Co-founder and COO), who closed the evening with heartfelt remarks about Rwanda’s potential to become a center of healthcare excellence, BAMCO’s long-term commitment, and the power of partnerships.
Mabeh Fang (Co-founder and COO)
Special thanks go to Theracos Bio for their unwavering support, and to the entire BAMCO Africa team, whose quiet dedication made the event seamless and meaningful.
